Clover Health Investments Corp. Class A (CLOV)

Over the past six months, Clover Health's stock price has been influenced by several key events. In January 2026, the company announced a significant 53% year-over-year membership growth in its Medicare Advantage PPO plans and projected its first full-year GAAP Net Income profitability in 2026, which caused the stock to soar by 10%. In February 2026, Clover Health reported its fourth-quarter and full-year 2025 results, reiterating its path to GAAP Net Income profitability, leading to stock price fluctuations around these announcements. In March 2026, the company announced a planned CFO transition while reaffirming its full-year 2026 financial guidance. On May 6, 2026, Clover Health reported its first-quarter 2026 results, showing a return to GAAP profitability with a net income of $27 million and a 62% year-over-year revenue increase to $749 million, although its EPS of $0.05 fell short of analyst expectations. This report led to a modest increase in the stock price. Despite these positive developments, the stock experienced general declines, with a 47.55% decrease between April 2025 and April 2026. As of May 8, 2026, the share price was $3.11, representing an 11.40% decline over the past year.

Demand for Clover Health's products and services exhibits seasonality, primarily driven by the Annual Election Period (AEP) for Medicare Advantage plans. This period runs annually from October 15 to December 7, during which Medicare-eligible individuals can enroll in or switch their Medicare Advantage plans. This typically leads to a surge in membership growth for the company following the AEP. The company has consistently reported strong membership growth after this period.

Clover Health Investments Corp. is a healthcare technology company offering Medicare Advantage plans, focusing on PPO and HMO options. The company uses its AI-powered Clover Assistant platform to provide data-driven insights to primary care physicians for improved chronic disease management and care coordination. Clover Health extends its technology through Counterpart Health, Inc., offering the Counterpart Assistant to third-party payors and providers, and also provides supplemental services like telehealth and transportation assistance. Clover Health launched Clover Therapeutics in 2019, a biopharmaceutical company researching therapies for age-related chronic diseases using data from its plan members.

Clover Health manages care for Medicare beneficiaries across multiple states. As of August 2021, the company had beneficiaries in 11 states: Arizona, Georgia, Kansas, New Jersey, New York, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, and Vermont. The company has expanded its service area to operate in 209 counties across nine states, including Alabama. More recently, as of March 2026, its coverage area specifically highlights Georgia, New Jersey, Pennsylvania, South Carolina, and Texas. Clover Health focuses on providing Medicare Advantage plans in largely rural or underserved areas.

In the past year, Clover Health has focused on improving its brand reputation through strong performance in quality measures and membership growth. The company achieved a 4.0 Star Rating for its PPO plans for payment year 2026. Its flagship PPO plan was also ranked as the number one PPO plan nationally on core HEDIS quality measures for the second consecutive year as of January 2026. However, the company has also faced challenges, including a lawsuit against HHS and CMS regarding its 2026 Star Ratings.

Clover Health Investments, Corp. has a diverse ownership structure, with institutional, insider, and retail investors holding shares. As of September 2025, retail investors held the largest portion with 50% ownership, followed by institutions and insiders. As of May 2026, institutional investors hold a total of 145,806,866 shares across 208 institutional owners. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Geode Capital Management, LLC, State Street Corp, Charles Schwab Investment Management Inc, Renaissance Technologies Llc, and The PNC Financial Services Group, Inc. Chamath Palihapitiya is noted as the largest individual shareholder, owning 11.56% of the company's shares. Vivek Garipalli, a co-founder and executive chairperson, held 18% of shares outstanding as of September 2025. Andrew Toy, the CEO, holds 0.8% of the shares.